GSK Biologicals opens site in Saint Amand les Eaux
16 Jan 2012 | Investment, Health Nutrition
Vaccine specialist rolls out new European production and packaging platform
In September 2006, GSK Biologicals announced that its new European production and packaging platform for vaccines, scheduled to start up in 2011, would be built near Valenciennes in Saint Amand les Eaux.
The Saint Amand site won this major investment program in a hotly-contested competition with other European regions. Its strengths: expertise in complex production processes, a strategic location and an exceptional business environment, including a highly skilled workforce.
- Total investment: €600 million
- Total jobs: 600
- Construction: 5 years
- Facilities: 7 buildings on a 17-hectare site
- Output: 300 million vaccines a year once the facility is up and running.
Today both the new jobs and the investment program are in place and the Saint Amand vaccine facility -- at the heart of GSK Biologicals’ development strategy -- is in full operation.
The investment strengthens GlaxoSmithKline’s presence in France, where it is the top foreign pharmaceutical group for employment, capital investment and R&D.
The vaccine platform is also the largest single investment in Northern France since Toyota opened its plant in 1997.